# Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

Study · id `cardio:ct-nct02422888` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02422888](<https://clinicaltrials.gov/study/NCT02422888>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02422888

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 110 participants.

## Technical summary

Registry record NCT02422888. Randomized; no masking; primary purpose treatment. Start 2015-05 (actual); primary completion 2017-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT02422888, source copy `cardio:ctgov-nct02422888-2018-05-03`, retrieved 2026-10-26)
- Started: 2015-05 (actual) (ClinicalTrials.gov record NCT02422888, source copy `cardio:ctgov-nct02422888-2018-05-03`, retrieved 2026-10-26)
- Primary completion: 2017-10 (actual) (ClinicalTrials.gov record NCT02422888, source copy `cardio:ctgov-nct02422888-2018-05-03`, retrieved 2026-10-26)
- Completion: 2019-10 (anticipated) (ClinicalTrials.gov record NCT02422888, source copy `cardio:ctgov-nct02422888-2018-05-03`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT02422888, source copy `cardio:ctgov-nct02422888-2018-05-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02422888-2018-05-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor
- Acronym: REDUCE-MVI
- Condition: Myocardial Infarction
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Prasugrel
- Lead sponsor: Amsterdam UMC, location VUmc
- Lead sponsor class: OTHER
- Collaborator: Erasmus Medical Center
- Collaborator class: OTHER
- Collaborator: Hospital San Carlos, Madrid
- Collaborator class: OTHER
- Collaborator: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Collaborator class: OTHER
- Collaborator: University Medical Center Nijmegen
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Amsterdam UMC, location VUmc (`cardio:org-amsterdam-umc-location-vumc`)
- Registry lists this organization as a collaborator: Erasmus Medical Center (`cardio:org-erasmus-medical-center`)
- Registry lists this organization as a collaborator: Hospital San Carlos, Madrid (`cardio:org-hospital-san-carlos-madrid`)
- Registry lists this organization as a collaborator: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (`cardio:org-academisch-medisch-centrum-universiteit-van-amsterdam-amc-662d32`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel (`cardio:pubmed-30586720`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial (`cardio:pubmed-32122216`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 639f1d128ef807c41b667eb2e12e191f301652781c42a879c84fbc385786ef89
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
